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Abstract
Objectives: Elevation of transaminases has been used
as a marker of hepatic ischemic injury and as a crucial
parameter for liver graft assessment. However,
analysis of serum transaminases has limitations
regarding the quantitative assessment of liver necrosis
and is not a reliable predictor of outcomes. 
Materials and Methods: We retrospectively reviewed
the medical records of all liver transplants (N = 238)
performed at the UMass Memorial Medical Center
from 2009 to 2013.
Results: Fourteen liver grafts showed high peak
aminotransferases alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) at > 1000 U/L. This
high aminotransferase group was compared with 
224 donors with low transaminase levels (ALT/AST 
< 1000 U/L). The high transaminase donors had a
median peak AST level of 3216 U/L (range, 1823-13 030
U/L) and ALT level of 2677 U/L (range, 812-7080 U/L).
The high transaminase donors showed higher levels of
lactate dehydrogenase, international normalized 
ratio, total bilirubin, and gamma-glutamyltransferase
compared with low transaminase donors; however,
only lactate dehydrogenase results reached statistical
significance. None of the grafts from the high
transaminase donors showed primary nonfunction.
Three-year graft and patient survival rates were similar
in both groups (75% vs 80% [P = .48] and 72% vs 82%
[P= .33], respectively). In an analysis of the discard rate
of livers over a 10-year period in the United States
using the Scientific Registry of Transplant Recipients
database, the discard rate of livers with high
aminotransferase levels was 69.14% compared with
22.23% for livers with low transaminase levels.
Conclusions: Liver grafts from donors with high
transaminase levels can lead to clinical results that are
similar to liver grafts from donors who had lower peak
transaminase levels.
Key words: Alanine aminotransferase, Aspartate amino -
transferase, Hepatic ischemic injury, Outcomes, Scientific
Registry of Transplant Recipients
Introduction
The shortage of suitable donor livers is the most
pressing problem facing liver transplantation today.
Currently, in the United States, 16 204 people are
waiting for a liver transplant, and mortality on the
wait list is 14%.1 This scenario has forced the
extrapolation of transplantability criteria of liver
grafts. Despite the fact that many livers are not
procured, about 3% of procured livers are not
transplanted because of concerns with organ quality
or other associated risks.2 One frequent reason why
many liver grafts are being discarded is the high level
of transaminases in the donor. Serum amino-
transferases, specifically, aspartate aminotransferase
(AST) and alanine aminotransferase (ALT), are
generally used as indicators of hepatocellular
damage and liver cell necrosis. However, there are
no clear upper limits of serum transaminases to
contraindicate a transplant.
Hypoxic hepatitis, also known as ischemic
hepatitis or shock liver, is the most frequent cause of
notably raised aminotransferases in the hospital and
intensive care unit. This acute liver injury is mainly
caused by insufficient oxygen uptake by hepatocytes.
Several mechanisms can lead to hypoxic hepatitis,
including hepatic ischemia as a consequence of
insufficient hepatic perfusion, insufficient oxygen
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extraction by the liver, systemic arterial hypoxemia,
and passive venous congestion.3 An imbalance in
metabolic supply and demand within the ischemic
organ results in profound tissue hypoxia and
microvascular dysfunction. Subsequent reperfusion
during transplant procedures further enhances the
activation of innate and adaptive immune responses
and cell death programs.4,5
The goal of our study was to compare the clinical
outcomes of liver transplants in our center from
donors who had peak AST or ALT beyond 1000 U/L
with donors with lower transaminase levels.
Materials and Methods 
Patients and study design
This retrospective analyses and presentation of data
from our transplant database were approved by the
University of Massachusetts Medical School Insti -
tutional Review Board. This investigation involved
238 patients who underwent orthotopic liver
transplant at UMass Memorial Medical Center from
January 1, 2009 through June 9, 2013. The study
population included patients over the age of 18 years
at the time of first transplant who received whole
liver allografts from brain-dead donors. Patients
included in the study were divided into 2 
groups according to the status of their donated
allograft: (1) livers from donors with peak AST or
ALT > 1000 U/L (n = 14) and (2) livers from donors
with peak AST or ALT < 1000 U/L (n = 224). This
transaminase cut-off was chosen empirically to
reflect a major increase of these values (> 20-times
baseline). The median follow-up after transplant was
1766 days (mean [standard deviation] of 1701 [508.2]
days).
Demographic and clinical characteristics of study
subjects were obtained through a retrospective
review of our center’s electronic medical records.
Information related to organ donors was collected
from the United Network for Organ Sharing (UNOS)
donor records using their DonorNet application.
Model for End-Stage Liver Disease (MELD) scores
utilized in this investigation were gathered from
UNet (also from UNOS) and reflected the recipient’s
MELD score as listed with UNOS at the time of
transplant. We could detect the exact position of the
recipient in the liver transplant wait list by recording
the match number. Donor liver biopsies were
obtained at the time of procurement as frozen-section
biopsies. Combined length of stay was calculated as
the sum of the intensive care unit length of stay and
hospital length of stay posttransplant. The donor risk
index was calculated according to the formula
specified by Feng and associates.6 Local organs were
transplanted according to the MELD allocation
policy. Imported organs, defined as an organ that
was declined by all transplant centers from at least 1
UNOS region, were allocated according to our
center’s preference. Asystole was determined at the
time the donor had no measurable pulse or was
estimated when the patient was found unconscious
prior to resuscitation. 
All transplant recipients were listed according to
standard protocols of our center and UNOS. All
operations were performed using standard surgical
techniques by the same surgical team. All livers were
preserved in University of Wisconsin solution and
implanted using piggyback technique without
portocaval shunt. Immunosuppression consisted of
a methylprednisolone bolus during the anhepatic
phase followed by prednisone taper, mycophenolate
mofetil, and tacrolimus.
Variables investigated included patient and graft
survival, surgical complications (eg, hepatic artery
thrombosis, reexploration rate, portal vein thrombosis,
and biliary complications), primary nonfunction, early
allograft dysfunction, postreperfusion syndrome, and
posttransplant recipient liver function tests. Early
allograft dysfunction was defined by the presence of
one or more of the following: (1) bilirubin ≥ 10 mg/dL
on day 7, (2) international normalized ratio (INR) ≥ 1.6
on day 7, and (3) AST or ALT > 2000 IU/L within the
first 7 days.7 Postreperfusion syndrome was defined
as a decrease in the mean arterial pressure of more
than 30% of the value observed in the anhepatic
stage, for more than 1 minute during the first 5
minutes after reperfusion of the graft.8 Primary
nonfunction was defined as death or retransplant
within 1 week after transplant associated with liver
failure in the absence of vascular complications.9 
In addition to our single-center study, we used the
Scientific Registry of Transplant Patients (SRTR)
database to analyze the discard rate of livers over a
10-year period in the United States, taking into
account donor high versus low transaminases levels
(see Figure 5). In total, 98.22% of transplanted livers
had transaminase levels < 1000 U/L compared with
1.78% of transplanted livers with transaminase levels
> 1000 U/L. 
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Statistical analyses
Data collection and statistical analyses were
performed using IBM SPSS Statistics (version 20.0;
SPSS Inc., Chicago, IL, USA) software. Data are
presented as mean and standard deviation for
continuous variables unless all data were tested for
normality using the method of Kolmogorov-Smirnov.
Categorical variables were compared using chi-square
tests, and continuous variables were analyzed using t
tests and analysis of variance where appropriate.
Kaplan-Meier survival analysis was used to evaluate
patient and graft survival, with the log-rank test used
to assess differences between survival curves.
Statistical significance was defined as P < .05.
Results 
Donor characteristics
All 238 donors included in this analysis were brain
dead. From this cohort, 14 donors had a peak AST or
ALT of > 1000 U/L (Table 1). Before organ recovery,
the median peak in this group was total bilirubin of
1.7 mg/dL (normal range from 0.3-1.9 U/L), gamma-
glutamyltransferase of 58 U/L (normal range from 
0-45 U/L), lactate dehydrogenase of 1769 U/L
(normal range from 140-280 U/L), INR of 2.5 (normal
range from 0.8-1.2), AST of 3216 U/L (normal range
from 10-40 U/L), and ALT of 2677 U/L (normal
range from 7-56 U/L). The median down time
(asystole) was 30 minutes (range, 0 to 99 min). Eleven
donor grafts (78.5%) from the high transaminase
group were imported from other regions after being
declined by other centers. Most of these livers went
to patients who were low on the list. The median
donor match sequence for all 14 patients who
received livers from high transaminase donors was
361 (range, 2-3506). Donors from the high trans -
aminase group were younger than donors from the
low transaminase group (median age of 40 vs 55
years; P = .005). The donor risk index in high trans -
aminase donors was lower than the risk index in low
transaminase donors, but this did not reach statistical
significance (1.89 vs 2.12; P = .1). In the high
transaminase group, 83.3% died of anoxia, compared
with 22.8% of low transaminase donors (P = .001). We
also found that high transaminase donors had higher
levels of lactate dehydrogenase, INR, total bilirubin,
and gamma-glutamyltransferase, but only lactate
dehydrogenase levels reached statistical significance
(1769 vs 325 U/L; P < .001).
Levels of AST and ALT usually peaked 24 to 48
hours before the time of organ recovery, when levels
were on average less than 50% of peak levels. It is
worth mentioning that, in this series, most donors
did not have a significantly associated increase in
INR or total bilirubin (Figure 1).
In all donors except for 2, a frozen-section liver
biopsy was performed at the time of procurement.
There were no signs of major steatosis, necrosis, or
inflammation in these grafts. Only 1 graft showed
15% to 20% necrosis. Frozen-section biopsy has been
shown to reliably assess inflammation and necrosis,
correlating with results shown with permanent-
section microscopy (Table 2).10 Donors were
numbered from 1 to 14 in Table 2, and each donor
donated a liver graft to the respective recipient
numbered from 1 to 14 in Table 3.
recipient characteristics
Recipient characteristics are summarized in Table 3.
Average patient age, average MELD scores at listing,
body mass index, sex, and ethnicity were similar in
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Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CIT, cold ischemia time; COD, cause of death; CVA, cerebrovascular accident;
INR, international normalized ratio; Tbili, total bilirubin
table 1. Characteristics of Donors Who Had Peak Transaminase Levels Greater Than 1000 U/L
COD Down AST, U/L ALT, U/L (first, Tbili, mg/dL INR (first, pH (first, Peak CIT, 
Time, min (first/peak/last) peak, last) (first, peak, last) peak, last) lowest, last) Sodium, mEq/L min
1 Anoxia 47 3030/13 030/46 4086/7080/150 0.2/1.1/0.2 3.0/7.4/1.1 6.7/6.7/7.2 547
2 Anoxia 43 3794/8464/7434 1463/3958/3958 0.4/1.7/1.7 3.8/3.8/3.0 7.2/7.0/7.4 152 577
3 Anoxia 19 44/7585/115 27/2911/78 0.6/3.9/3.7 1.9/3.4/2.0 7.4/7.1/7.4 173 648
4 Anoxia 99 556/5833/2887 346/3395/2096 0.3/2.0/2.0 1.1/3.7/3.7 7.2/7.1/7.2 135 508
5 Anoxia none 18/4912/124 12/2561/387 1.2/2.2/2.2 1.0/1.9/1.2 7.3/7.3/7.5 136 511
6 Anoxia 30 1123/3295/1112 292/754/469 0.2/1.3/1.2 1.2/2.9/2.8 7.0/6.9/7.4 141 552
7 Anoxia 46 76/3138/1710 94/1062/939 0.4/2.0/2.0 2.0/2.9/2.8 6.5/6.5/7.4 148 540
8 Head trauma None 84/2794/1446 44/2794/1714 0.4/1.1/0.7 1.2/1.3/1.2 7.3/7.1/7.4 152 600
9 Anoxia 15 1204/2272/513 1692/2331/688 0.8/1.8/1.8 1.1/2.5/1.5 6.7/6.7/7.5 155 540
10 Anoxia 30 1500/1823/1823 2003/2855/1828 0.4/0.6/0.7 2.5/2.5/1.7 7.2/7.2/7.4 149 510
11 CVA none 1429/1429/372 296/812/337 1.7/1.9/1.1 1.2/1.1/1.2 7.3/7.1/7.4 152 546
12 Anoxia 40 1345/1345/371 454/454/245 0.7/0.7/0.4 1.2/1.5/1.5 7.1/7.1/7.2 141 468
13 Head trauma none 540/1239/1221 243/794/794 0.3/0.7/0.6 1.8/1.8/1.4 7.2/7.1/7.4 145 585
14 Anoxia 80 434/1096/138 206/234/109 0.3/0.5/0.5 1.0/1.1/1.0 7.0/7.0/7.4 138 480
recipients of grafts from high versus low trans -
aminase donors. The median MELD score of livers
with elevated transaminase was 19.4. Indications for
transplant and immunosuppression were com parable
in both groups. As mentioned above, recipients were
numbered from 1 to 14 in Table 3, and each recipient
received a liver graft from the respective donor
numbered from 1 to 14 in Table 2. 
transplant outcomes
There were no differences in surgical complications
(eg, hepatic artery thrombosis, reexploration rate,
portal vein thrombosis, biliary complications),
intensive care unit and hospital stay (4 vs 4 days 
[P = .87] and 12.5 vs 10.5 days [P = .58]), and use of
blood products during the first 24 hours (including
the transplant procedure) between groups. None of
the livers from the high transaminase group had
primary nonfunction (no significant difference from
the low transaminase group). The rate of early allograft
dysfunction was 14%, which is similar to control and
data in the literature.11-13 Liver function tests of
recipients during the first week showed that these
livers recovered fast, with most of these parameters
getting close to normal levels within the first week
(Figure 2). The rate of postreperfusion syndrome was
20%. None of these 14 patients presented with severe
biliary complications. Of the 14 patients, 5 (36%)
underwent endoscopic retro grade cholangio -
pancreatograms, but only 3 (21%) had anastomotic
strictures that were treated successfully with stents.
Figure 3 shows Kaplan-Meyer patient survival
curves for both groups of patients. The 1- and 3-year
survival curves of the 14 recipients of high
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table 2. Biopsy Results of Donors Who Had Peak Transaminase Levels
Greater Than >1000 U/L 
Donor Biopsy Result
1 < 5% macrosteatosis, 0% microsteatosis, no necrosis, no
inflammation
2 2% macrosteatosis, microsteatosis mild, necrosis < 1%,
inflammation 1/4
3 5% macrosteatosis, 10% microsteatosis, bridging centrolobular
necrosis 15% to 20%
4 no steatosis, mild inflammation, no necrosis
5 < 5% macrosteatosis, 15% to 20% microsteatosis, no inflammation,
no necrosis, cholestasis
6 no steatosis, no inflammation, no necrosis
7 no steatosis, no inflammation, no necrosis, cholestasis
8 no steatosis, no inflammation, no necrosis, cholestasis
9 < 5% macrosteatosis, < 5% microsteatosis, no necrosis, mild
inflammation, cholestasis
10 < 5% macrosteatosis, no inflammation, no necrosis
11 minimal steatosis, mild inflammation, no necrosis, cholestasis
12 10% to 15% macrosteatosis, 10% to 15% microsteatosis, no
necrosis, no inflammation
13 no steatosis, mild inflammation, no necrosis, cholestasis
14 no biopsy
table 3. Characteristics and Outcomes of Recipients of Grafts With Peak Transaminase Levels Greater Than 1000 U/L
Sex Ethnicity MELD Diagnosis HCC Donor Match IPF Follow-up, d LOS, d Number of Number
Sequence of PRBC in OR of ERCPs
M W 10 ETOH No 2.708 No 1923 11 0 0
M H 17 ETOH No 2.026 No 1787 10 5 0
M H 13 ETOH No 2.374 Yes 1892 4 7 0
M W 17 NASH No 386 No 1784 34 6 4
M W 19 ETOH No 335 No 1091 15 9 0
F W 12 HCV/ETOH No 2.483 No 1373 17 11 0
M W 25 HCV Yes 170 No 1433 19 12 2
M W 22 HCV Yes 17 No 2419 7 4 0
M W 16 HCV No 33 No 1747 19 4 0
F W 31 HCV/ETOH No 17 No 2039 15 7 3
M W 15 NASH No 3.506 No 1332 20 6 3
M W 23 ETOH No 1.110 No 1172 9 8 0
F W 28 HCV No 12 No 1028 15 3 0
M W 24 HCV/ETOH Yes 2 Yes 2799 21 4 2
Abbreviations: ERCP, endoscopic retrograde cholangiopancreatogram; ETOH, alcoholic hepatitis; F, female; HCC, hepatocellular carcinoma; H, Hispanic;
HCV, hepatitis C virus; IPF, initial poor function; LOS, length of stay; M, male; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic
steatohepatitis; OR, operation room; PRBC, packed red blood cells; W, white 
Figure 1. Donor Liver Function Tests From Admission to Day of Procurement
in 14 Donors With High Transaminase Levels  
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
usually peaked 24 to 48 hours after the initial ischemic insult and decreased
thereafter. Those donors did not show increase in international normalized
ratio (INR) and total bilirubin before procurement.
transaminase donor livers were worse than those in
the 224 recipients of low transaminase donor livers
(85% vs 88% [P = .332] and 71% vs 84% [P = .08],
respectively), but this did not reach statistical
significance. Graft survival was not significantly
different between the high transaminase and low
transaminase groups (1-year graft survival of 85% vs
87% [P = .483] and 3-year graft survival of 71% vs
83% [P = .12]) (Figure 4).
In the SRTR database analyses, we found that, in
the United States, 1.78% of all liver grafts offered for
transplant between 2002 and 2012 had either AST or
ALT above 1000 U/L. The discard rate for these livers
was 69.14% compared with 22.23% for low trans -
aminase donors (< 1000 U/L). We noted a decreased
discard rate of livers with high transaminase levels
over time after implementation of the MELD
allocation system in February 2002 (Figure 5).
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Figure 2. Recipient Transaminases, Total Bilirubin, Alkaline Phosphatase, and International Normalized Ratio in the First 7
Days Posttransplant in the High Transaminase Group (n = 14)
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; AP, alkaline phosphatase; INR,
international normalized ratio; TBILI, total bilirubin
Abbreviations: ALT, alanine aminotransferase; AST, aspartate amino -
transferase; AP, alkaline phosphatase; INR, international normalized ratio;
TBILI, total bilirubin
Abbreviations: ALT, alanine aminotransferase; AST, aspartate
aminotransferase
Figure 3. Survival Curves of Patients Who Received Organs From Donors With
High Transaminase Versus Lower Transaminase Levels 
Figure 4. Survival Curves of Grafts From Donors With High Transaminase
Versus Lower Transaminase Levels 
Discussion
Many usable liver grafts are being discarded
unnecessarily. Tector and associates2 showed that
68% of recipients in their series (388 of 571) received
expanded criteria donor grafts. Patient and graft
survival rates were similar between recipients of
standard criteria organs and expanded criteria donor
grafts (1-year graft survival of 84% vs 80% and 2-year
graft survival of 78% vs 77%, respectively). In
addition to good patient and graft outcomes, they
showed an increase in the percentage of wait list
removals for transplant (P < .01), decrease in the
percentage of removals for death or too sick to
transplant (P = .04), and increased rate of transplants
per patient per year on the wait list compared with
the national average.2
Throughout the body, AST and ALT levels are
widely distributed. Although AST is found primarily
in heart, liver, skeletal muscle, and kidney, ALT is
found primarily in liver and kidney, with lesser
amounts in heart and skeletal muscle. In addition,
ALT is exclusively cytoplasmic, whereas AST is 
both mitochondrial and cytoplasmic in all cells.14
Traditionally, elevation of transaminases has been
broadly used as a marker of hepatic ischemic injury
and as a crucial parameter for liver graft assessment.
However, serum transaminase analysis has limi -
tations regarding quantitative assessment of liver
necrosis. It is well established that levels of AST and
ALT do not necessarily reflect the underlying
necroinflammatory activity.15
Indeed, several factors other than liver disease
(eg, muscle injury, heart infarct, hemolysis) can
increase AST and ALT activities.16 These conditions
are frequent in donors who have died secondary to
trauma or a cardiac event. In addition, these levels
may not reflect the number of necrotic cells. These
limitations seem to result from instability of cellular
enzymes. Clearance depends on the rate at which the
enzymes are released from cells and the rate at which
they are taken up by sinusoidal-lining cells.17
Therefore, the serum level observed in a single assay
does not necessarily reflect the total amount released
or the extent of ischemic damage. The half-life of AST
in the circulation is 17 ± 5 hours, whereas that of ALT
is 47 ± 10 hours.16 Therefore, it is necessary to
consider the curve of transaminases and not only the
peak when considering organs from donors with
high transaminase levels. The typical pattern of
transaminase elevation during the course of ischemic
insult shows an initial dramatic rise of both
transaminase and lactate dehydrogenase levels
within 12 to 24 hours after the initiating event.18
Fuhrmann and associates showed that increasing
AST levels for more than 24 hours is associated with
worse liver injury.5 Usually, aminotransferase levels
fall more than 50% within 3 days after stabilization
and elimination of the underlying causing condition.
Specifically, AST levels decline toward baseline levels
earlier than ALT levels during this recovery period
because of the shorter half-life of AST.16 It is also
important to consider other tissue sources to explain
the increase of transaminases, including trauma,
hemolysis, and heart attack. Likewise, it is important
to consider that other abnormal liver function tests
associated with high transaminase levels can portend
major liver insult (eg, high INR, high total bilirubin).
In these cases, a liver biopsy before organ pro -
curement or at the time of procurement can be of
crucial importance in the decision-making process to
accept or discard the graft.
Many organs from donors with increasing trans -
aminases are discarded because increased AST/ALT
results are usually considered surrogates of liver
injury/necrosis. It has been shown that the presence
of ischemic hepatitis in critically ill patients is
associated with a 30-day mortality of more than
50%.5 It is extremely common to find elevated
transaminases during events that lead to brain-death
donation. However, it is not clear to what extent the
level of transaminases of the donor can predict
clinical outcomes after transplant. A 2008 consensus
conference addressing the use of expanded criteria
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Figure 5. Discard Rate of Livers From Donors With High Transaminases Over
Time in the US Scientific Registry of Transplant Recipients Between 2002 and
2012
donor grafts came to the conclusion that there is no
clear upper limit above which the organ should not
be transplanted and that liver procurement should
not be excluded based on these enzymes alone.19
clinical evidence of the impact of transaminase
level and outcomes 
Despite the fact that some single-center reports have
shown correlations between absolute transaminase
values and outcomes,12,20 it is generally accepted that
these values are not good predictors of outcome. In a
Cox regression analysis of 52 donor variables on liver
graft survival of 5150 liver transplants, there was no
negative effect when transaminases were above 200
U/L.21 In a Cox regression analysis by Feng and
associates of SRTR data that included 20 023 liver
transplants, donor AST levels were not predictors of
graft outcome; thus, donor AST level was not
incorporated in the donor risk index.6 Likewise, the
European donor risk index does not include donor
AST as a predictor of liver graft outcomes.22 The
levels of recipient transaminases posttransplant are
also poor predictors of graft outcomes. Using a Cox
regression analysis of 213 consecutive transplants,
Rosen and associates showed that AST is predictive
of graft survival only when it is markedly elevated
(AST maximum > 5000 U/L).23
However, in a predictor score system (SOFT
score) that included transaminases in the risk
calculation, Rana and associates found that AST >
140 IU/L and ALT > 100 IU/L were risk factors for
worse outcome.24
There are 2 previous single-center studies that
specifically investigated the impact of elevated
transaminases as the primary variable. The first
retrospective study was from Radunz and colleagues
from Essen, Germany, who reported their experience
with transplants of livers from 8 brain-dead donors
who had markedly elevated levels of AST (median of
1400 U/L; range 500-7538 U/L) and ALT (median of
1026 U/L; range, 308-9179 U/L). In their series, liver
enzymes had decreased in 6 of 8 donors, but there was
no associated significant steatosis. None of these grafts
had primary nonfunction, and all patients were alive
at follow-up with the exception of 1 who died because
of unrelated issues. Protocol biopsies at 3 to 6 months
posttransplant showed portal fibrosis grade 1 in 3
patients and grade 2 in 1 patient.25
The second report was by Mangus and associates
from the United States. In this retrospective study of
1348 consecutive deceased donor (including 64
donors after cardiac death) transplants, the recipients
were categorized into 3 groups based on the
elevation of serum ALT: normal/mild elevation 
(0-499 U/L), moderate elevation (500-999 U/L), and
severe elevation (≥ 1000 U/L). In this cohort, there
were 1259 patients included in the normal/mild
group (93%), 34 in the moderate group (3%), and 55
in the severe group (4%). Results from this analysis
failed to demonstrate any differences in early graft
function or graft and patient survival based on
evaluation of peak donor ALT. Although 49% of the
liver grafts with elevated donor ALT demonstrated
evidence of hepatocyte necrosis on reperfusion
biopsies, there was no correlation with peak of
recipient serum transaminases after transplant.
Subgroup analysis did not show an association
between percent of total graft steatosis and higher
donor ALT levels or increased risk of hepatocyte
necrosis. The authors also found that ALT elevation
was more associated with anoxia as a cause of death,
and there was a direct association with the duration
of donor asystole time.26
Graft and recipient matching for livers with high
transaminase levels
We preferred to allocate livers with high trans -
aminase levels to recipients with lower MELD scores
and poor quality of life (despite the fact that in our
series there was no statistically significant difference
in MELD scores between the 2 groups). The rationale
is that high MELD patients with major portal
hypertension and associated comorbidities are less
likely to tolerate a rough reperfusion than low MELD
patients.27
Donors from the high transaminase group were
significantly younger than donors in the low
transaminase group. We are more hesitant to accept
livers with high transaminases from older donors,
since older age is a significant risk factor for poor
outcomes.28 In addition, it is well-known that older
age increases susceptibility of livers to ischemia.29-31
We also try to expedite allocation of donors with high
transaminases to decrease the cold ischemia time and
minimize ischemic damage. Despite the fact that
most of these organs came from another region and
needed first to be declined by all transplant centers of
one region, our cold ischemia time was relatively
short (9.0 h ± 46 min, mean ± SD). These livers could
be successfully allocated to recipients low on the list
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(median donor match sequence for all 14 patients
who received livers from high transaminase donors
was 361), going to a patient as low as the 3506th
position on the wait list.
The main limitation of our study was the
retrospective nature of the analysis and the fact that
the number of donors with elevated transaminases
(AST or ALT > 1000 U/L) was small (n = 14). In
addition, nonrandomized studies have unavoidable
biases related to organ allocation. The allocation
system for imported organs (11 of 14) was not based
on MELD score but based on “rescue allocation,”
since many were open offers and allocated to less
sick patients (with lower MELD scores). In addition,
we did not perform postreperfusion biopsies, and we
have not tried to correlate transaminase levels with
pretransplant biopsy results because of the small
number of cases and the fact that only 1 liver showed
necrosis. It is also well known that frozen-section
biopsies have limitations regarding determination of
degree of steatosis and fibrosis. Our analysis did not
include the number of organ offers to our center from
donors who had high AST or ALT and were not
accepted for transplant. In addition, it is not possible
to determine whether the presence of high trans -
aminase levels was the main reason for declining a
liver graft by other centers since the reasons for
refusal in the UNOS organ allocation software
application are generic and the true refusal reasons
could have been a combination of unfavorable donor
characteristics. We also did not analyze the history of
alcohol abuse in this population. Another limitation
was that many times it was impossible to determine
exactly when asystole happened, and it was usually
estimated when the patient was found unconscious
before resuscitation. 
Our series of livers from donors with high
transaminase levels showed that these livers can be
safely used and demonstrated results similar to those
from 2 other centers.25,26 Although the number of
patients in the study arm was small, our data
demonstrated similar patient and graft survival
between recipients of organs from donors with high
transaminase and low transaminase levels. We
showed here that it is feasible to use liver grafts from
donors with markedly elevated AST/ALT levels
with reasonable results. Our analyses of the SRTR
database showed that the discard rate of these livers
has been declining over time, possibly reflecting the
increasing gap between demand and supply of
organs and the increasing experience with standard
criteria livers. Donors with high transaminase levels
can be safely used to increase the organ donor pool.
Judicious selection of these grafts, by eliminating
additional risk factors (older age, significant steatosis,
and necrosis), and expeditious allocation may con -
tribute to favorable outcomes. The effects of adequate
recipient matching require further characterization
when using these organs.
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